Monoclonal Gammopathies and the Kidney

ISBN-13: 9789048161997 / Angielski / Miękka / 2010 / 300 str.

G. Touchard;Dr Aucouturier; O. Hermine

Opis

The kidney involvement in monoclonal gammopathies is a fascinating field of research and of great concern to clinical practice. The book is divided into four parts.
The first one is devoted to "the culprits" and includes contributions from leading investigators in B-cell proliferations, immunoglobulin synthesis, secretion and structure, light chain uptake and metabolism in the kidney.
The second and third parts are devoted to "the victims": the tubule and the glomerulus. New insights into pathophysiology, clinical and histological features, treatment of renal lesions and therapy of B-cell proliferations are reported in myeloma cast nephropathy, Fanconi's syndrome, Randall-type monoclonal immunoglobulin deposition disease and non amyloid organized monoclonal immunoglobulin deposits. In the last part, immunoglobulinic amyloidosis is considered with a round table devoted to stem cell transplantation and new promising therapies in AL amyloidosis.

Spis treści

List of Principal Authors. Preface: Kidney disease-inducing monoclonal immunoglobulins; J-L. Preud'Homme. Part I: The Culprits: The Plasma Cell Dyscrasias. 1. Physiopathology of malignant B cell lymphoproliferations; K. Lassoued, D. Ghez. 2. Immunoglobulin synthesis and secretion; D.O. Beenhouwer, K.R. Chintalacharuvu, S.L. Morrison. 3. Immunoglobulin decreased solubility diseases: pathologies of the V domains? M. Cogné, H.R. Galea, C. Sira, C. Decourt. 4. Megalin, cubilin and immunoglobulin light chains; H. Birn, M. Leboulleux, S.K. Moestrup, P.M. Ronco, P. Aucouturier, E.L. Christensen. Part II: The Victim: The Tubule. 5. Pathophysiology of myeloma kidney; P.W. Sanders. 6. Myeloma cast nephropathy: clinical presentation; A. Hummel, P. Lesavre, H.-H. Noël, D. Droz, P. Aucouturier, D. Chauveau, M. Touam, J.-P. Grünfeld. 7. New therapeutic approaches of the myeloma patient with and without renal failure; J.P. Fermand. 8. Adult Fanconi syndrome due to monoclonal immunoglobulin light chains: an underdiagnosed disease with unexpected clinical and pathologic heterogeneity; P. Ronco, B. Mougenot, B. Moulin, M. Bouiller, T. Messiaen, P. Aucouturie. 9. Monoclonal immunoglobulin light chains associated to Fanconi syndrome; P. Aucouturier, S. Déret, M. Leboulleux, P. Ronco. Part III: The Victim: The Glomerulus. 10. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposit; G. Touchard. 11. Morphological aspects in light chain deposition diseas; F. Ferrario, S. Curioni, G. Arrigo, C. Pozzi, G. Banfi. 12. Renal monoclonalimmunoglobulin deposition disease (MIDD): The Columbia experience; J. Lin, G.S. Markowitz, A.M. Valeri, N. Kambham, W.H. Sherman, G.B. Appel, V.D. D'Agati. 13. Monoclonal cryoglobulinemia kidney; G. D'Amico. 14. Fibrillary glomerulonephritis: defining the disease spectrum; V.D. D'Agati, G.B. Appel, G.S. Markowitz, L. Truong, S. Seshan, D. Un Kim, G. Sacchi. 15. Glomerulonephritis with organized immunoglobulin deposits: fibrillar and microtubular deposits are associated with distinct immunological features; F. Bridoux, O. Coldefy, J.-M. Goujon, M. Bauwens, A. Sechet, J.-L. Preud'Homme, G. Touchard. Part IV: Immunoglobulinic Amyloidosis. 16. Clinical features and management of amyloidosis; P.N. Hawkins. 17. Fibrillogenesis and therapy of amyloidosis; J.S. Wall, M. Schell, R. Hrncic, F.J. Stevens, A. Solomon. 18. Immunoglobulin light chain amyloidosis and the kidney; M.A. Gertz, M.Q. Lac, A. Dispenzieri. 19. Treating primary systemic amyloidosis with stem cell transplantation: outcomes in renal amyloidosis; R.L. Comenzo. 20. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic al amyloidosis: a report on 21 patients; P. Moreau, V. Leblond, P. Bourquelot, T. Facon, A. Huynh, D. Caillot, O. Hermine, M. Attal, M. Hamidou, G. Nedellec, A. Ferrant, B. Audhuy, R. Bataille, N. Milpied, J.-L. Harousseau. 21. Presentation of the French multicentre randomized trial comparing intensive and conventional treatment for AL amyloidosis; A. Jaccard. 22. Amyloidosis; J.P. Fermand, A. Jaccard, O. Hermine. Oral Communications.